| Name | Title | Contact Details |
|---|
VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies. The company is developing a broad pipeline of therapeutics targeting ROR1 in oncologic indications with high unmet medical need.
Refuge is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient`s body.
ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types.
Aminex Therapeutics, Inc. is focused on bringing its breakthrough discoveries to the clinic to improve the lives of cancer patients.
Certus International Inc is a Bedford, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.